- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 369-383 of
1,261 results
2004 Exhibit: EX2004 Stipulation and Order Regarding Trial of the MPI Ozempic Li...
Document
IPR2024-00009, No. 2004 Exhibit - EX2004 Stipulation and Order Regarding Trial of the MPI Ozempic Litigation, In re Ozempic Semaglutide Patent Litigation, No 22 MD 03038 CFC, Dkt 245 D D...
|
|
Cite Document
2019 Exhibit: EX2019 Novo Nordisk Production Letter, In re Ozempic Semaglutide ...
Document
IPR2024-00009, No. 2019 Exhibit - EX2019 Novo Nordisk Production Letter, In re Ozempic Semaglutide Patent Litigation, No 22 MD 03038 CFC D Del Oct 17, 2023 REDACTED (P.T.A.B. Jan. 26...
|
|
Cite Document
2008 Exhibit: EX2008 Claim Construction Order, In re Ozempic Semaglutide Paten...
Document
IPR2024-00009, No. 2008 Exhibit - EX2008 Claim Construction Order, In re Ozempic Semaglutide Patent Litigation, No 22 MD 03038 CFC, Dkt 148 D Del July 25, 2023 (P.T.A.B. Jan. 26, 2024)
|
|
Cite Document
2005 Exhibit: EX2005 Nov 29, 2023 Email from E Goldschlager to Counsel, re IPR2...
Document
IPR2024-00009, No. 2005 Exhibit - EX2005 Nov 29, 2023 Email from E Goldschlager to Counsel, re IPR2023 00724 – Request for Conference Call (P.T.A.B. Jan. 26, 2024)
|
|
Cite Document
2010 Exhibit: EX2010 Excerpt of Novo Nordisk’s Second Amended Disclosures to D...
Document
IPR2024-00009, No. 2010 Exhibit - EX2010 Excerpt of Novo Nordisk’s Second Amended Disclosures to Dr Reddy’s Laboratories Ltd and Dr Reddy’s Laboratories, Inc, In re Ozempic Semaglutid...
|
|
Cite Document
2016 Exhibit: EX2016 Transfer Order, In re Ozempic Semaglutide Patent Litigation...
Document
IPR2024-00009, No. 2016 Exhibit - EX2016 Transfer Order, In re Ozempic Semaglutide Patent Litigation, No 22 MD 03038 CFC, Dkt 1 D Del Aug 5, 2022 (P.T.A.B. Jan. 26, 2024)
|
|
Cite Document
... William J Jusko, PhD Regarding Invalidity of US Patent No 10,335,462, In re Ozempic Semaglutide Patent Litigation, No 22 ...
Document
IPR2024-00009, No. 2025 Exhibit - EX2025 Excerpt of Opening Expert Report of William J Jusko, PhD Regarding Invalidity of US Patent No 10,335,462, In re Ozempic Semaglutide Patent Litigation, No 22
|
|
Cite Document
2022 Exhibit: EX2022 Notice of Service for Defendants’ Initial Invalidity Contention...
Document
IPR2024-00009, No. 2022 Exhibit - EX2022 Notice of Service for Defendants’ Initial Invalidity Contentions, In re Ozempic Semaglutide Patent Litigation, No 22 MD 03038 CFC D Del Oct 20, 2022...
|
|
Cite Document
1035 Exhibit: Lund, Emerging GLP 1 Receptor, 6 EXPERT OP ON EMERGING DRU...
Document
IPR2024-00009, No. 1035 Exhibit - Lund, Emerging GLP 1 Receptor, 6 EXPERT OP ON EMERGING DRUGS 607 2011 (P.T.A.B. Oct. 20, 2023)
|
|
Cite Document
1016 Exhibit: US Patent Application Pub No US20070010424
Document
IPR2024-00009, No. 1016 Exhibit - US Patent Application Pub No US20070010424 (P.T.A.B. Oct. 20, 2023)
|
|
Cite Document
1002 Exhibit: Prosecution history excerpts for US Patent No 10,335,462
Document
IPR2024-00009, No. 1002 Exhibit - Prosecution history excerpts for US Patent No 10,335,462 (P.T.A.B. Oct. 20, 2023)
|
|
Cite Document
1046 Exhibit: Yun, Pharmacokinetic, 31 J CLINICAL PHARMACY THERAPEUTICS ...
Document
IPR2024-00009, No. 1046 Exhibit - Yun, Pharmacokinetic, 31 J CLINICAL PHARMACY THERAPEUTICS 469 2006 (P.T.A.B. Oct. 20, 2023)
|
|
Cite Document
1064 Exhibit: Monami, Effects of Glucagon Like Peptide 1 EXPER DIABETES RSCH...
Document
IPR2024-00009, No. 1064 Exhibit - Monami, Effects of Glucagon Like Peptide 1 EXPER DIABETES RSCH 1 2012 (P.T.A.B. Oct. 20, 2023)
|
|
Cite Document
1042 Exhibit: WO 9111457
Document
IPR2024-00009, No. 1042 Exhibit - WO 9111457 (P.T.A.B. Oct. 20, 2023)
|
|
Cite Document
1003 Exhibit: Declaration of John Bantle, MD
Document
IPR2024-00009, No. 1003 Exhibit - Declaration of John Bantle, MD (P.T.A.B. Oct. 20, 2023)
|
|
Cite Document
